Lorenz M, Staib-Sebler E, Gog C, Petrowsky H, Köhne C H, Encke A
Department of General Surgery, University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
Oncology. 1998 Jan-Feb;55(1):53-8. doi: 10.1159/000011835.
A pilot study was performed to evaluate the tolerance and efficacy of a hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) and folinic acid (FA) in patients with unresectable liver metastases from colorectal carcinoma.
In 11 patients, 135 applications of high-dose HAI of 5-FU/FA were administered. All patients had been intra-arterially pretreated, and 2 of them had received an additional intravenous therapy. The chemotherapy regimen consisted of a weekly HAI of FA 500 mg/m2 over 1 h, immediately followed by HAI of 5-FU over 24 h. Four patients received a 5-FU starting dose of 2,000 mg/m2 and 7 patients of 2,400 mg/m2. One course consisted of 12 weekly applications interrupted by 1 week after 6 applications and 4 weeks after 12 applications.
The applied regimen caused only mild side effects. Nausea and vomiting were the most frequently side effects with 36 episodes out of 135 applications (WHO grade > or = 3: 2 episodes). Diarrhea was a minor problem occurring with 8 episodes (WHO grade > or = 3: 1 episode). There was no evidence of myelosuppression, hand-foot syndrome, neurotoxicity, and biliary sclerosis. A partial remission was observed in 3 patients, and a disease stabilization in 2 patients while the disease progressed in 6 patients under high-dose HAI of 5-FU/FA.
The present pilot study demonstrates that the weekly high-dose HAI of 5-FU/FA is well tolerated and associated with very mild toxicity. Because of the encouraging response rate in patients, whose disease progressed under the conventional intra-arterial therapy either with 5-FU/FA or 5-fluorodeoxyuridine, this regimen seems to be an effective second-line treatment and should be evaluated in nonpretreated patients in a phase II study.
开展一项初步研究,以评估肝动脉灌注(HAI)5-氟尿嘧啶(5-FU)和亚叶酸(FA)对无法切除的结直肠癌肝转移患者的耐受性和疗效。
对11例患者进行了135次5-FU/FA高剂量HAI治疗。所有患者均接受过动脉内预处理,其中2例还接受了额外的静脉治疗。化疗方案为每周1次HAI,先输注1小时500mg/m²的FA,随后立即进行24小时的5-FU HAI。4例患者5-FU起始剂量为2000mg/m²,7例患者为2400mg/m²。一个疗程包括12次每周治疗,在6次治疗后中断1周,12次治疗后中断4周。
所应用的方案仅引起轻微副作用。恶心和呕吐是最常见的副作用,135次治疗中有36次发作(世界卫生组织分级≥3级:2次发作)。腹泻是一个小问题,出现8次发作(世界卫生组织分级≥3级:1次发作)。没有骨髓抑制、手足综合征、神经毒性和胆汁硬化的证据。3例患者观察到部分缓解,2例患者病情稳定,而6例接受5-FU/FA高剂量HAI治疗的患者病情进展。
本初步研究表明,每周高剂量HAI应用5-FU/FA耐受性良好,毒性非常轻微。由于在接受5-FU/FA或5-氟脱氧尿苷传统动脉内治疗病情仍进展的患者中反应率令人鼓舞,该方案似乎是一种有效的二线治疗方法,应在II期研究中对未接受预处理的患者进行评估。